AstraZeneca and Oxford's COVID-19 Vaccine Shows Promise in Elderly Adults
AstraZeneca and the University of Oxford published Phase II clinical trial results for their COVID-19 vaccine in The Lancet. The data shows the vaccine is safe and offers a similar immune response in all adults.
This comes within a week of news that both the Pfizer and BioNTech vaccine program and the Moderna program are wrapping their Phase III trials and expecting to apply for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) within days. Some sources suggest the Pfizer-BioNTech group will submit for their EUA tomorrow, Friday, November 20. The FDA advisory committee for vaccines is meeting on December 8, 9 and 10, and there is a possibility those two vaccines will receive EUA on the 10th.
The AstraZeneca-Oxford group is lagging behind a bit, but the data published today shows their vaccine is promising as well. The study was in 560 healthy adults, including 240 who were 70 years old or older.
Although COVID-19 can infect people at any age, older people are at significantly greater risk of severe illness and death than younger people, although the disease can kill people at all ages.
Please, to access the full article visit Bio Space